Does levodopa-carbidopa intestinal gel in Parkinson’s disease patients increase the risk on polyneuropathy?
Objective: To analyze the influence of the overall levodopa exposure on the risk of polyneuropathy (PN) in levodopa-carbidopa intestinal gel (LCIG)-infusion treated patients with Parkinson’s…Patient perspectives of using the ND0612 mini-pump
Objective: To evaluate patient and caregiver usability and satisfaction with the mini-pump that will be used for continuous ND0612 delivery among patients with moderate-severe PD.…Impact of levodopa-induced dyskinesias on Health-related Quality of Life. Results from the French COPARK study.
Objective: To assess the impact of LIDs on HRQoL in this large sample of unselected Parkinson’s Disease (PD) patients and to assess the factors related…Decision making under uncertainty in medicated and un-medicated Parkinson’s disesase
Objective: To evaluate decision making under risk in Parkinson’s disease patients, both medicated and un-medicated states probing constituent cognitive operations driving choice. Background: Prior literature…ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD
Objective: Characterize the levodopa pharmacokinetic profile derived from continuous subcutaneous (SC) administration of ND0612. Background: Continuous levodopa/carbidopa (LD/CD) infusion is considered the optimal delivery route…Factors determining the motor outcome of STN DBS in PD patients: Evidence for Dual Actions
Objective: We investigated factors determining the motor outcome of STN DBS in patients with Parkinson disease (PD). Background: The STN DBS has revolutionized the management…Association of Single Nucleotide Polymorphism in MAOB and Risk of Levodopa-Induced Dyskinesias in Parkinson’s Disease
Objective: To identify genetic risk factors for developing levodopa-induced dyskinesias (LID) in patients with Parkinson’s disease (PD). Background: LID are common complications in PD, but…Identification of the optimal carbidopa concentration in subcutaneously administered ND0612
Objective: To identify the concentration of subcutaneous (SC) carbidopa (CD) that provides optimal bioavailability of a concomitant fixed concentration of levodopa (LD) when administered via…Combined Surgical Therapies for Optimal Management of Advanced Parkinson’s Disease
Objective: We report a case of a patient with advanced PD who began LCIG for refractory motor fluctuations while continuing longstanding STN-DBS. Background: LCIG and…Specific Bdnf variants are associated with suboptimal response to levodopa but not to other dopaminergic medications or deep brain stimulation in Parkinson’s disease
Objective: We examined the impact of rs6265 and other brain-derived neurotrophic factor (Bdnf) variants in two subject cohorts: 1) early-stage Parkinson’s disease (PD) subjects from…
- « Previous Page
- 1
- …
- 49
- 50
- 51
- 52
- 53
- …
- 62
- Next Page »